17(ss)-hydroxysteroid dehydrogenase type 1 is a predictive factor in premenopausal hormone receptor positive breast cancer treated with tamoxifen

被引：0
|
作者：
Kallstrom, A-C
Salme, R.
Ryden, L.
Gunnarsson, C.
Nordenskjold, B.
Stal, O.
机构：
[1] Helsingborg Hosp, Helsingborg, Sweden
[2] Univ Hosp, Linkoping, Sweden
[3] Univ Lund Hosp, S-22185 Lund, Sweden
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S84 / S85
页数：2
相关论文
共 50 条
  • [11] Is ERα a Tamoxifen Predictive Factor in ERα Negative Breast Cancer in Premenopausal Women?
    Kallstrom, A-C
    Ferno, M.
    Jonsson, P. E.
    Landberg, G.
    Nordenskjold, B.
    Stal, O.
    CANCER RESEARCH, 2010, 70
  • [12] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Daisuke Shimizu
    Takashi Ishikawa
    Mikiko Tanabe
    Takeshi Sasaki
    Yasushi Ichikawa
    Takashi Chishima
    Itaru Endo
    Breast Cancer, 2014, 21 : 557 - 562
  • [13] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Shimizu, Daisuke
    Ishikawa, Takashi
    Tanabe, Mikiko
    Sasaki, Takeshi
    Ichikawa, Yasushi
    Chishima, Takashi
    Endo, Itaru
    BREAST CANCER, 2014, 21 (05) : 557 - 562
  • [14] Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer
    Hilborn, Erik
    Stal, Olle
    Jansson, Agneta
    ONCOTARGET, 2017, 8 (18) : 30552 - 30562
  • [15] Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer
    Conte, Benedetta
    Poggio, Francesca
    Del Mastro, Lucia
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1357 - 1362
  • [16] Expression of 17β-hydroxysteroid dehydrogenase type 1 in gastric cancer
    Frycz, Bartosz Adam
    Murawa, Dawid
    Wysocki-Borejsza, Maciej
    Marciniak, Ryszard
    Murawa, Pawel
    Drews, Michal
    Jagodzinski, Pawel Piotr
    BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (07) : 651 - 657
  • [17] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
    Tevaarwerk, Amye J.
    Wisinski, Kari B.
    O'Regan, Ruth M.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
  • [18] Tidal chemotherapy in premenopausal patients with hormone receptor positive breast cancer
    Luo, Qing-qing
    Huang, Jian-bo
    Wu, Yu-tuan
    Li, Xin
    Zhao, Chun-xia
    Wu, He
    Dai, Wei
    Wu, Kai-nan
    Kong, Ling-quan
    MEDICAL HYPOTHESES, 2017, 102 : 4 - 7
  • [19] Efficacy of adjuvant tamoxifen in hormone receptor-positive premenopausal breast cancer patients according to the body mass index
    Altundag, Kadri
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Ozisik, Yavuz
    CANCER RESEARCH, 2015, 75
  • [20] Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Ozdemir, Nuriye Y.
    Zengin, Nurullah
    Yazici, Ozan
    Sever, Ali R.
    Altundag, Kadri
    JOURNAL OF BUON, 2016, 21 (01): : 27 - 34
12345